Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals (MIRM)
NASDAQ:MIRM
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 521.31M | $ 336.89M | $ 186.37M | $ 77.06M | $ 19.14M |
| Gross Profit | $ 420.73M | $ 255.25M | $ 139.34M | $ 64.69M | $ 17.23M |
| Operating Income | $ -22.14M | $ -87.61M | $ -109.15M | $ -131.22M | $ -173.41M |
| EBITDA | $ 17.21M | $ -48.97M | $ -136.49M | $ -122.85M | $ -65.39M |
| Net Income | $ -23.36M | $ -87.94M | $ -163.41M | $ -135.66M | $ -83.99M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 383.33M | $ 280.31M | $ 286.33M | $ 151.72M | $ 156.54M |
| Total Assets | $ 842.81M | $ 670.75M | $ 646.62M | $ 352.91M | $ 294.65M |
| Total Debt | $ 317.31M | $ 317.76M | $ 308.14M | $ 2.19M | $ 2.61M |
| Net Debt | $ 20.63M | $ 95.26M | $ 21.82M | $ -25.82M | $ -28.73M |
| Total Liabilities | $ 528.12M | $ 445.11M | $ 397.95M | $ 210.87M | $ 174.44M |
| Stockholders' Equity | $ 314.69M | $ 225.64M | $ 248.67M | $ 142.04M | $ 120.21M |
| Cash Flow | |||||
| Free Cash Flow | $ 54.87M | $ 9.33M | $ -91.05M | $ -120.41M | $ -151.78M |
| Operating Cash Flow | $ 55.83M | $ 10.32M | $ -70.94M | $ -120.14M | $ -132.76M |
| Investing Cash Flow | $ -23.95M | $ -90.13M | $ -107.20M | $ 7.70M | $ 48.55M |
| Financing Cash Flow | $ 40.14M | $ 17.70M | $ 336.60M | $ 109.09M | $ 73.47M |